Kymriah (tisagenlecleucel) Receives Second FDA Approval to Treat Appropriate Patients with Large B-Cell Lymphoma

Basel, May 1, 2018 - Novartis today announced the US Food and Drug Administration (FDA) has approved Kymriah ® (tisagenlecleucel) suspension for intravenous infusion for its second indication - the treatment of adult patients with relapsed or...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news